{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-217954","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.639554+00:00","generated_at":"2026-06-24T00:55:06.232101+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Fulcrum Therapeutics promotes Mel Hayes to COO with salary increase and stock option grant","bullets":["Mel Hayes promoted from chief commercial officer to chief operating officer effective August 9, 2022.","Annual base salary increased to $453,000 retroactive to July 1, 2022.","Granted option to purchase 137,000 shares at $7.40 per share, vesting over four years.","Hayes previously served as CCO since September 2021; prior roles include Sanofi-Genzyme and Bioverativ.","Employment agreement setting terms for severance and change-in-control benefits filed as Exhibit 10.1."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-217954","json":"https://secwatch.observer/filing/0001193125-22-217954.json","markdown":"https://secwatch.observer/filing/0001193125-22-217954.md","text":"https://secwatch.observer/filing/0001193125-22-217954.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522217954/0001193125-22-217954-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522217954/d346123d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:55:06.232101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0013d14a38","claim":"Mel Hayes changed role as Chief Operating Officer at Fulcrum Therapeutics, Inc..","evidence_excerpt":"On August 11, 2022, Fulcrum Therapeutics, Inc., or Fulcrum, announced that its board of directors promoted Mel Hayes, its current chief commercial officer, to the position of chief operating officer effective August 9, 2022, such date the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522217954/0001193125-22-217954-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}